Wofsy D
University of California-San Francisco.
Immunol Ser. 1993;59:221-36.
Extensive studies in lupus-prone mice strongly suggest that mAbs to CD4 may be effective in SLE. By virtue of their selectivity for distinct cells within the immune system, anti-CD4 mAbs may be both more potent and less toxic than current therapies for SLE. In addition, their potential to block the host immune response to therapy may provide a critical advantage for anti-CD4 compared to other forms of mAb therapy. The problem of generalized immune suppression remains a significant obstacle to the use of anti-CD4 in humans, but it may be minimized by the use of mAb fragments or mAb isotypes that can reversibly inhibit immune function without depleting CD4+ T cells.
对狼疮易感小鼠的广泛研究有力地表明，抗CD4单克隆抗体可能对系统性红斑狼疮有效。由于其对免疫系统内不同细胞的选择性，抗CD4单克隆抗体可能比目前治疗系统性红斑狼疮的疗法更有效且毒性更小。此外，与其他形式的单克隆抗体疗法相比，它们阻断宿主对治疗的免疫反应的潜力可能为抗CD4单克隆抗体提供关键优势。全身性免疫抑制问题仍然是抗CD4单克隆抗体在人类中应用的重大障碍，但通过使用可在不消耗CD4+ T细胞的情况下可逆地抑制免疫功能的单克隆抗体片段或单克隆抗体亚型，这一问题可能会最小化。
